OncoSec Medical Incorporated (NASDAQ:ONCS)’s share price was up 4% during trading on Thursday . The stock traded as high as $2.55 and last traded at $2.08. Approximately 6,211,052 shares traded hands during trading, an increase of 157% from the average daily volume of 2,416,182 shares. The stock had previously closed at $2.00.

Several equities analysts have recently commented on ONCS shares. ValuEngine upgraded shares of OncoSec Medical from a “strong sell” rating to a “sell” rating in a research report on Friday, July 14th. Maxim Group restated a “buy” rating and set a $5.00 price target on shares of OncoSec Medical in a research report on Friday, September 1st. Finally, HC Wainwright restated a “buy” rating and set a $6.00 price target on shares of OncoSec Medical in a research report on Thursday. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the stock. OncoSec Medical currently has an average rating of “Buy” and an average target price of $5.33.

OncoSec Medical (NASDAQ:ONCS) last announced its earnings results on Wednesday, October 25th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.05).

COPYRIGHT VIOLATION NOTICE: This news story was first published by Watch List News and is the property of of Watch List News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.watchlistnews.com/oncosec-medical-incorporated-oncs-trading-up-4/1695848.html.

OncoSec Medical Company Profile

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.

Receive News & Ratings for OncoSec Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.